Dermavant Presents Final Data From ADORING 3 LTE Study On VTAMA Cream, 1% At 2024 Fall Clinical Dermatology Conference; 51.9% Achieved Complete Disease Clearance And Remained Treatment-Free For ~80 Days; FDA PDUFA Action Date Expected Q4 2024
Portfolio Pulse from Benzinga Newsdesk
Dermavant presented final data from the ADORING 3 LTE study on VTAMA cream, showing 51.9% of patients achieved complete disease clearance and remained treatment-free for about 80 days. The FDA PDUFA action date is expected in Q4 2024.
October 25, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Dermavant, a subsidiary of Roivant Sciences (ROIV), presented positive final data from the ADORING 3 LTE study on VTAMA cream. 51.9% of patients achieved complete disease clearance, and the FDA PDUFA action date is expected in Q4 2024.
The positive results from the VTAMA cream study are significant for Roivant Sciences as it indicates potential future revenue from a successful product. The upcoming FDA decision adds regulatory risk but also potential upside if approved.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80